BioGaia AB (OTCPK:BGLAF)
$ 10.5 0 (0%) Market Cap: 989.13 Mil Enterprise Value: 887.96 Mil PE Ratio: 31.83 PB Ratio: 6.64 GF Score: 98/100

Q3 2023 Biogaia AB Earnings Call Transcript

Oct 20, 2023 / 07:30AM GMT
Release Date Price: $9
Operator

This call is being recorded. Welcome to BioGaia Q3 report for 2023. (Operator Instructions) Now, I will hand the conference over to CEO, Theresa Agnew; and CFO, Alexander Kotsinas. Please go ahead.

Theresa Agnew
BioGaia AB - President and CEO

This is Theresa Agnew. Welcome to our management statement for Q3 of 2023. I have to say I'm very excited to be here. This is my first such quarterly meeting, so excited to present the results today for BioGaia.

Just a little bit of an introduction on myself. So I became the CEO on September 25. My background, if you have researched a little about me, is mainly in health care. I've worked in healthcare my entire career and I have a science background.

I've spent about 21 years at Johnson & Johnson in the consumer sector for consumer healthcare products, OTC products as well as medical devices. My experience there spans marketing, sales, general management, strategic planning, business development as well. I also spent a brief period at Essilor which is the number-one manufacturer of prescription

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot